CD274 and hepatocellular carcinoma: Moreover, they contain tumor-infiltrating lymphocytes expressing PD-1, and PD-L1 expression is not significantly different between primary and metastatic lesions, making HCC a good candidate for treatment with PD-1 inhibitors, such as nivolumab [9,28].